MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
AgeX Therapeutics Cash Conversion Cycle 2011-2026 | AGE
Annual Cash Conversion Cycle AgeX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.96 K | -10.5 K | -8.72 K | -8.22 K | -1.9 K | -1.13 K | - | -246 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -246 | -10.5 K | -5.67 K |
Quarterly Cash Conversion Cycle AgeX Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | -2.21 K | -11 K | -58.2 K | - | -4.61 K | -4.99 K | -31.4 K | - | -15.1 K | -2.92 K | -16.9 K | - | -3.65 K | -22.5 K | -53.5 K | - | -702 | -636 | -355 | - | 3.45 K | -148 | -48.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.45 K | -58.2 K | -12.5 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 7.71 | 1.65 % | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
7.85 K | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Heron Therapeutics
HRTX
|
751 | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Incyte Corporation
INCY
|
-54.7 | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
184 | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
Inovio Pharmaceuticals
INO
|
1.91 K | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
CorMedix
CRMD
|
359 | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
163 | $ 8.33 | 0.97 % | $ 260 M | Israel |